Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Common Equity (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Common Equity for 6 consecutive years, with $123.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Common Equity fell 48.91% to $123.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $123.1 million, a 48.91% decrease, with the full-year FY2025 number at $123.1 million, down 48.91% from a year prior.
  • Common Equity was $123.1 million for Q4 2025 at TScan Therapeutics, down from $144.0 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $255.2 million in Q2 2024 to a low of -$60.0 million in Q2 2021.
  • A 5-year average of $140.5 million and a median of $148.3 million in 2022 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: skyrocketed 599.57% in 2021, then crashed 48.91% in 2025.
  • TScan Therapeutics' Common Equity stood at $160.8 million in 2021, then crashed by 38.15% to $99.4 million in 2022, then surged by 51.73% to $150.9 million in 2023, then skyrocketed by 59.72% to $241.0 million in 2024, then tumbled by 48.91% to $123.1 million in 2025.
  • Per Business Quant, the three most recent readings for TCRX's Common Equity are $123.1 million (Q4 2025), $144.0 million (Q3 2025), and $176.7 million (Q2 2025).